Most problems (infections, reduced potency, unexpected reactions) come from poor technique or improper storage, not from the peptides themselves
Gastrointestinal effects are the most frequently reported side effects and include: Nausea (1224% of patients): Often most pronounced during treatment initiation and dose escalation, typically improving over time Diarrhea (1323% of patients): May be transient or persistent, requiring dietary modifications Vomiting (611% of patients): Can lead to dehydration if severe or prolonged Constipation (617% of patients): May require increased fiber intake and hydration Abdominal pain or discomfort (610% of patients): Usually mild to moderate in severity Decreased appetite : Therapeutic effect but may be excessive in some individuals These gastrointestinal symptoms generally diminish over several weeks as the body adjusts to the medication
Redefine 1 trial finds cagrilintidesemaglutide combo delivers over 20% weight loss in majority of patients Summary: The Phase IIIa REDEFINE 1 trial found that once-weekly CagriSema produced unprecedented weight reductions in adults with overweight or obesity, with 60% achieving 20% weight loss and 23% losing 30% or more
Rights and permissions About this article Cite this article Townsend, D., Tew, K
The goal is to provide strong quality without inflated costs
This content does not constitute medical or clinical advice
